<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426452</url>
  </required_header>
  <id_info>
    <org_study_id>CPTK787A2121</org_study_id>
    <nct_id>NCT00426452</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers</brief_title>
  <official_title>A Phase IB, Open Label, Single Center, Drug-drug Interaction Study of Oral 1250 mg of PTK787/ZK 222584 Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor (Omeprazole) in Healthy Sterile or Postmenopausal Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will determine the effect of acidic drugs such as proton-pump inhibitors on the
      pharmacokinetics of Vatalinib under fasting and fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the effect of multiple doses of a proton-pump inhibitor on the pharmacokinetics of a single dose of Vatalinib under fasting and fed conditions.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of a single dose of Vatalinib before and after a proton-pump inhibitor under fasting and fed conditions as assessed by adverse events, laboratory values, electrocardiograms, and vital signs.</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vatalinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Healthy female

          -  Surgically sterile or post-menopausal

          -  At least a weight of 50 kg and have a body mass index (BMI) â‰¤33.0

          -  Non-smokers or those who smoke 25 cigarettes or less per day Exclusion criteria

          -  Use of certain prescription and over the counter drugs

          -  Having received an investigational drug within 30 days prior to dosing

          -  Donation of plasma or donation or loss of whole blood prior to administration of the
             study medication

          -  Any clinically significant laboratory tests

          -  Abnormal cardiac function

          -  A positive test for HIV, Hepatitis B or C

          -  A positive alcohol test or drug test

          -  Known allergy to Vatalinib or Omeprazole

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism and excretion or drugs.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <last_update_submitted>November 18, 2009</last_update_submitted>
  <last_update_submitted_qc>November 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitor</keyword>
  <keyword>Vatalinib</keyword>
  <keyword>Proton-pump inhibitors</keyword>
  <keyword>Omeprazole</keyword>
  <keyword>Healthy Postmenopausal Female Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

